Patent intelligence · US
US 11739297
Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor
Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor
Patent details — US 11739297
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 29, 2023
- Expiration
- Aug 24, 2043
- Applicant
- Carisma Therapeutics Inc.
- Claims
- 10
- CPC classes
- A61K, A61K2239/13, A61K2239/21, A61K2239/22
Quick answer
US 11739297 (Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor) is held by Carisma Therapeutics Inc.. Status: granted. Granted Aug 29, 2023. Expires Aug 24, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Carisma Therapeutics Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K2239/13, A61K2239/21, A61K2239/22, A61K38/00, A61K40/17
More from Carisma Therapeutics Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11739297?
US 11739297 (Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor) is held by Carisma Therapeutics Inc.. Status: granted. Granted Aug 29, 2023. Expires Aug 24, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11739297?
Carisma Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 11739297 expire?
Our index shows an expiration date of Aug 24, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.